Cargando…
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
BACKGROUND: Dipeptidyl peptidase-4 (DPP4) is commonly targeted to achieve glycemic control and has potent anti-inflammatory and immunoregulatory effects. Recent structural analyses indicated a potential tight interaction between DPP4 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...
Autores principales: | Zhou, Jiang-Hua, Wu, Bin, Wang, Wen-Xin, Lei, Fang, Cheng, Xu, Qin, Juan-Juan, Cai, Jing-Jing, Zhang, Xiao-Jing, Zhou, Feng, Liu, Ye-Mao, Li, Hao-Miao, Zhu, Li-Hua, She, Zhi-Gang, Zhang, Xin, Yang, Juan, Li, Hong-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716296/ https://www.ncbi.nlm.nih.gov/pubmed/33344548 http://dx.doi.org/10.12998/wjcc.v8.i22.5576 |
Ejemplares similares
-
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022) -
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020) -
Rapid Identification of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides from Ruditapes philippinarum Hydrolysate
por: Liu, Rui, et al.
Publicado: (2017)